Optimer Pharmaceuticals, Inc. (NASDAQ" OPTR) has filed an open shelf registration last night with the SEC that will allow it to sell up to $100 million in any of the following types of securities: Common Stock; Preferred Stock; Debt Securities; Warrants; Units.
The company is focused on discovering, developing and commercializing anti-infective products, and initial development efforts are to treat gastrointestinal infections and related diseases where current therapies have limitations. The company currently has two late-stage anti-infective product candidates, OPT-80 and Prulifloxacin.
OPT-80 is the lead product candidate and is an antibiotic that is currently in two Phase III registration trials for the treatment of Clostridium difficile-infections, also known as Clostridium difficile-associated disease, the most common nosocomial diarrhea. Prulifloxacin is an antibiotic that is currently in two Phase III trials for the treatment of infectious diarrhea in travelers, a community-acquired infection often caused by a broad range of bacteria. The company developing additional product candidates using its proprietary technology, including its OPopS drug discovery platform.
We frequently cover secondary offerings and other issues around IPO’s that include back door plays into IPO’s, spin-offs, restructurings, recapitalizations, and more in our open email distribution list.
Optimer shares are down 1.4% at $6.21 today, and its 52-week trading range is $5.90 to $10.42. Its current market cap is $172.95 million.
Jon C. Ogg
March 28, 2008
Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at firstname.lastname@example.org; he does not own securities in the companies he covers.